Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02816684 · ClinicalTrials.gov registry record · Phase 2
Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety
A Phase 2 study, sponsored by University of Central Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02816684: Completed Phase 2 study, sponsored by University of Central Florida.
NCT02816684 is a Phase 2 study that has completed, run by University of Central Florida. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02816684, a Phase 2 study, has completed, sponsored by University of Central Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Among children, social anxiety is a common, severe and chronic disorder. Social Effectiveness Therapy for Children (SET-C) is an empirically supported treatment with significant potential to impact the lives of children with this severe and chronic disorder. The proposed Pegasys-VR™ system will distinctly enhance its utility, as it will allow dissemination to a broad variety of clinical settings including schools as well as traditional outpatient clinics. Its use for the treatment of social skills deficits will offer a superior solution for mental health personnel, solving many of the resource and logistic barriers that they currently face. The final product will address cost and practical issues by disseminating an empirically-supported treatment that was rigorously built and tested. Using VE will make the traditional social skills therapy programs program cost-effective and patient-centric, allowing even clinicians with little background/training in behavior therapy to have tools not typically available to them.
Primary Outcome
self-report measure of social anxiety disorder in children
Interventions
- BEHAVIORAL Pegasys-VR
- BEHAVIORAL Social Effectiveness Therapy for Children
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
What the finished NCT02816684 record still lists
NCT02816684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Pegasys-VR is the first listed.
NCT02816684 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02816684 about?
NCT02816684 is a clinical study titled "Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety". Among children, social anxiety is a common, severe and chronic disorder. Social Effectiveness Therapy for Children (SET-C) is an empirically supported treatment with significant potential to impact the lives of children with this severe and chronic disorder. The proposed Pegasys-VR™ system will dist...
What is the current status of trial NCT02816684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2016-06. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02816684?
The interventions under investigation include: Pegasys-VR (BEHAVIORAL), Social Effectiveness Therapy for Children (BEHAVIORAL).
Who is sponsoring clinical trial NCT02816684?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02816684's enrollment target sits among peer trials
43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia